📰 Valuating News
Page 2 - Valuating News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Valuating. Real-time updates on events, politics, business and more.
June 3, 2023
Results presented today at ASCO 2023 and concurrently published in The Lancet Oncology demonstrate meaningful clinical benefit including antitumor activity, confirmed objective response rate
June 2, 2023
AstraZeneca PLC on Friday reported positive results from planned interim analysis of a phase three trial evaluating its Imfinzi drug in gastric and gastroesophageal junction cancers. The... | June 2, 2023
June 1, 2023
NORTH CHICAGO - AbbVie today announced the results of the Phase 2 SLEek study evaluating upadacitinib alone and in combination [ABBV-599 high dose ] in adults with moderately to severely active... | June 1, 2023
June 1, 2023
By Colin Kellaher Pfizer on Thursday reported positive results from a pair of Phase 3 studies evaluating the efficacy, safety and tolerability of the novel investigational antibiotic... | June 1, 2023
June 1, 2023
NEW YORK - TG Therapeutics, Inc. , today announced the details of an upcoming oral presentation, highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI in patients with... | June 1, 2023
May 31, 2023
-- Only Sjögren's syndrome Phase 2 trial to meet the primary endpoint in both patient population types -- -- Patients with moderate-to-severe systemic disease activity (ESSDAI score =5) treated
May 29, 2023
Media Release Appointment of Charles River Laboratories to run Immutep’s preclinical toxicology study evaluating the safety and toxicity of IMP761Forms a key step prior to... | May 29, 2023
May 26, 2023
Positive data support the potential of plixorafenib to induce deep and durable benefit for patients with BRAF-mutated (V600+) cancers In the V600+ population benefit was observed in both MAPK-inhibitor
May 25, 2023
The Librexia program evaluating milvexian is unrivaled as the most comprehensive factor XIa inhibitor clinical development program to date and will provide extensive data from nearly 50,000 patients,... | May 25, 2023
May 25, 2023
The application to the European Medicines Agency is supported by data from the Phase 3 CARTITUDE-4 study, evaluating the safety and efficacy of cilta-cel in the treatment of patients with relapsed... | May 25, 2023